BRAF and cancer: Importantly, the chance to integrate cancer vaccines in future combinatorial immunotherapy regimens extends beyond checkpoint inhibitors to include immune costimulatory agonists (i.e., OX40 and 4-1BB), immunomodulatory agents, as well as selected inhibitors of oncogenic kinases (i.e., BRAF and MEK) [76].